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VITAL ROLE OF HERV-K IN MALIGNANT DISEASE PROGRESSION 
PROVIDES A NOVEL TARGET FOR CANCER THERAPEUTICS 
 
 CATHERINE NGOC HO  
ABSTRACT 
Human Endogenous Retroviruses (HERV) are segments of the human 
genome that are viral in origin and occupy approximately 8% of the human 
genome, which is nearly 3 times as much as functional protein coding genes 
(3%). Although most are defective due to accumulation of post insertional 
mutations, Human Endogenous Retrovirus Type K (HERV-K) retains the ability to 
produce functional particles and is activated during progression of malignant 
disease. The resulting proviral products have been associated with 
tumorigenesis through their presumed role in malignant cell production. While 
therapeutics that focus on HERV-K inhibition have not been manufactured, 
current Federal Drug Administration (FDA)-approved antiretroviral therapies are 
capable of decreasing expression of HERV-K in cancer cells. In summary, 
antiretroviral drugs may serve as a promising class of new anticancer drug by 
targeting and decreasing expression of HERV-K proteins.	
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INTRODUCTION 
HERVs Background 
Human Endogenous Retroviruses (HERV) are segments of the human 
genome that are viral in origin. The genetic material derives from retroviruses, a 
broad group of RNA viruses that are able to integrate a DNA copy of the viral 
genome into a host’s cell. If integrated into a germ line cell, the proviral element 
has the potential to become an integral and inherited part of the host genome, 
which can have significant consequences on the carrier (Hohn, Hanke, and 
Bannert 2013). Once germ lineage cells acquire the provirus, the HERV is a 
permanent part of the genome unless acted on by selective processes and 
genetic drift (Broecker et al. 2016). HERVs that lead to decreased fitness of the 
host are removed via negative selection. Those that provide a net neutral or 
positive effect will inevitably accumulate changes that result in eventual 
functional decay. Many HERVs are rendered inactive due to extensive post-
insertional recombinations, deletions, and mutations that occurred over the 
course of human evolution. A common event that leads to HERV inactivation is 
homologous recombination between two long terminal repeats (LTRs) that 
removes the majority of functional viral information, resulting in a solo LTR (Lenz 
2016) 
	2 
  
 
Figure 1: Formation of Solo LTRs. A typical HERV sequence contains 4 genes 
(gag, pro, pol, and env) flanked by two LTR sequences. These LTRs that can 
undergo recombination events that lead to a solo LTR. In the figure, the small, 
black vertical lines represent the mutations that inevitably accumulated over time 
(Lenz 2016). 
 
 
Due to incorporation of exogenous retroviruses that were present 
approximately 2-40 million years ago, the human population, regardless of 
genetic background, shares an extensive number of HERV loci in their genome. 
Consequently, HERVs occupy approximately 8% of the human genome, which is 
nearly 3 times as much as functional protein coding genes (3%). Despite their 
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relatively large presence in the human genome, accumulation of post insertional 
modifications over the course of human evolution has diminished the activity of 
the majority of acquired HERVs (Mullins and Linnebacher 2012). Additionally, 
there are also cell mechanisms, such as chromatin remodeling, RNA silencing, 
and antiretroviral protein inhibition, that are initiated to actively counter HERV-K 
activity and that result in an apparent lack of function.  
Despite epigenetic silencing factors, the HERV-K family, one of the most 
recently acquired families of HERVs, contains highly conserved proviruses from 
the HML-2 subgroup; nearly 90 proviruses have maintained open reading frames 
(ORFs) that encode functional viral proteins (Subramanian et al. 2011). In most 
cells, HERV-K transcription and translation is muted by epigenetic control, but 
the placenta and the testes basally produce HERV particles (Pérot et al. 2012). 
However, intact ORFs and subsequent amplification have turned HERV-K into 
the largest contributor of retroviral-derived proteins in the human genome 
(Hanke, Hohn, and Bannert 2016). The transcriptional influence over an unknown 
number of genes imposed by proviral sequences provides additional incentive to 
research these viral insertions. 
A typical HERV K sequence, seen in Figure 1, contains transcribable gag, 
pro, pol, and Env genes flanked on each side by a 5’ and 3’ LTR. While the LTR 
regions do not transcribe functional proteins, they are capable of regulating 
transcription of HERV and host genes due to a transcriptional promoter and 
enhancer core (Chuong, Elde, and Feschotte 2016). Normally, the full HERV-K 
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encodes for structural proteins (George et al. 2011), but slippery sites and a 
resulting ribosomal frameshift leads to production of a protease (Pro) and a 
polymerase (Pol), where the latter exhibited reverse transcriptase (RT) and 
integrase (IN) activity (Hohn, Hanke, and Bannert 2013). Due to the various and 
diverse HERV-K loci found throughout the genome, traditional products of viral 
structural proteins can also be formed. The Env gene encodes different proteins 
depending on the manner its transcript is spliced. If exons are not removed, then 
the transcript should produce a standard retroviral envelope protein. However, 
functional Env proteins are rarely described, likely due to the accumulation of 
mutations (Hurst and Magiorkinis 2017). Three other proteins, Rec, Np9, and hel, 
are produced upon removal of several exons within the Env transcript. 
Depending on the product of the Env transcript, most HERVs are either referred 
to as type 1 provirus (expressing Np9) or a Type II provirus (expressing Rec). 
Np9 differs from Rec via a 292 base pair frameshift deletion. The differences in 
their splicing details are indicated in Figure 2. While hel is not translated into a 
protein, Rec and Np9, on the other hand, are translated into products that are 
often associated with malignancies. 
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Figure 2: Alternative Splicing of HERV-K Env Produces Different Products. 
HERV transcripts can produce various products from the Env gene. Type II 
proviruses express Rec while type I proviruses express Np9, which has a 292 
base pair deletion in the gene sequence indicated by the black bar. Hel does not 
have a protein coding capabilities and is poorly described in literature (Hohn, 
Hanke, and Bannert 2013). 
  
Physiological effects of HERVs 
As mentioned previously, HERVs that are integrated into the human 
genome can elicit significant consequences, both positive and negative, on the 
host. Hypothetically, conservation of these HERVs thus far suggests that their 
proteins also provide beneficial effects to mask the detrimental effects to the 
host, and several studies have indicated possible evolutionary advantages of 
HERVs.  One of the most notable examples is the expression of HERVs during 
placentogenesis (Kurth and Bannert 2010). From the perspective of the mother, 
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the placenta is identified as an allogenetic tissue. However, in the 
syncytiotrophoblast, which acts as an interface between the maternal tissues and 
the trophoblast, there are significantly high levels of HERV Env proteins that are 
not seen in the trophoblast. A common function of the viral envelope is to 
facilitate fusion of the cell membranes of the virus and its target cell while 
escaping detection of the immune system.   In the context of placentogenesis, 
expression of HERV Env may therefore prevent rejection of the fetus by 
providing local immunological tolerance. The expression of HERV-K during 
placentogenesis is presumed to hold a similar role (Kurth and Bannert 2010). 
Another study also noted the HERV-K Rec proteins play a role in fetal 
development and differentiation (Andersson et al. 2002). Other hypothesized 
functions include, but are not limited to, promotion of genetic diversity (Brandt et 
al. 2005), repair of chromosomes (Teng, Kim, and Gabriel 1996), and role in 
telomerase production (Eickbush 1997). 
Recently, HERV-K expression has also been indicated in brain 
development and function. In 2014, Karki et al demonstrated that transfecting 
human neuronal cell lines with a vector carrying HERV-K (HML-2) Env leads to 
increased transcription of brain-derived neurotrophic factor (BDNF) and nerve 
growth factor (NGF). This would result in increased neuronal viability and 
protection from neurotoxicity (Bhat et al. 2014).  Increased expression of βIII-
tubulin, a microtubule that is found almost exclusively in neurons that contribute 
to their neoplastic abilities, was also observed in cells with increased expression 
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of HERV-K env (Karki et al. 2013). This, however, may be a double edged sword; 
in the context of malignant diseases, this element of the tubulin family has also 
been associated with tumor aggressiveness, resistance to chemotherapy and 
poor patient survival (Karki et al. 2013). Contrary to its proposed role in brain 
development and function, HERV-K has demonstrated an association with 
several CNS related diseases. These conflicting roles suggest that HERV-K’s 
neuroprotective actions may be secondary to its pathogenic influence as a 
means to ensure survival of the host and conservation of its proviral sequence in 
the human genome. 
Despite its possible influence on reproduction and development, HERV K 
evolution is not meant to primarily benefit the host and have therefore been 
linked with pathologies. For several decades, HERVs have been associated with 
human chronic diseases such as autoimmune conditions and cancer (Hohn, 
Hanke, and Bannert 2013). For example, there are several studies investigating 
its role in the propagation of autoimmune disease such as rheumatoid arthritis 
(RA) and multiple sclerosis (MS). In RA, an autoimmune disorder where chronic 
inflammation of synovial joints culminates in cartilage and bones damage, 
molecular assays have showed a significant increase in the HERV-K gag, when 
compared to healthy controls (Freimanis et al. 2010). Expression is further 
enhanced by the presence of exogenous viral particles and antibodies generated 
for the HERV-K antigen may exhibit cross reactivity through similar properties of 
host proteins (Freimanis et al. 2010). MS is a disease where the insulating 
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sheaths of neurons in the central nervous systems are damaged by an 
inflammatory process, resulting in impaired neural communication. Compared to 
RA, disease etiology of MS is not as well understood and the likely multifactorial 
origins of pathogenesis make HERV-K contributions controversial. While data 
shows an elevation in the expression for HERV-K in these pathologies, their 
exact role in pathogenesis is not clearly understood and more research is 
necessary before confirming an association. However, HERV-’K’s role in 
malignant diseases has been extensively researched, and its expression is 
presumed to play a crucial role in the development or maintenance of several 
cancers. Table 1 contains a list of the malignant diseases that are often 
associated with increase in HERV-K HML-2 activity. 
 
Table 1: List of cancers associated with activity of HERV-K particles (Hohn, 
Hanke, and Bannert 2013). 
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NECESSITY OF RESEARCH AND SPECIFIC GOALS 
Currently, many cancer treatments focus on inhibiting the progression of 
the cell cycle and exploiting biological differences between healthy cells and 
cancerous cells in order to target malignant cells. However, these “unique” 
targets used to identify malignant cells are also found in normal healthy stem 
cells, particularly in the hair follicle, intestine, and hematopoetic system. While 
effective, cancer chemotherapeutics can have dangerous side effects if 
improperly used; In order to prevent permanent tissue damage or patient death, it 
is critical that the dosing regimens of these traditional anticancer agents must be 
carefully designed and administrated. Targeting HERV-K transcription and 
translation would provide a novel target for pharmacological cancer therapeutics. 
Additionally, the epigenetic suppression of HERV- K in most cell types implies 
that it is unlikely that normal cells rely on the transcripts of HERV-K on a day to 
day basis (Hanke, Hohn, and Bannert 2016). Because of this, the repercussions 
of overdose are unlikely to be as severe as those seen with anticancer drugs. 
Therefore, targeting and inhibiting expression of these proviral sequences should 
not introduce additional harm to a patient. Yet, considering its basal levels of 
expression in a subset of healthy tissues and hypothesized contribution to 
reproductive processes, removal of the HERV-K sequences through new 
technologies such as CRISPR in hopes of healthier progeny should be avoided. 
However, temporary inhibition of HERV-K transcription and expression in 
cancerous diseases via administration of antiretroviral therapies may be a 
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potential way to treat and manage pathological states associated with raised 
HERV-K expression. 
The specific aim of this thesis is to cross reference studies to identify how 
HERV-K plays a vital role in cancer development and speculate on applications 
of HERV-K targeted antiretroviral therapies. This paper also intends to suggest 
plausible directions of future therapeutic research. 
 
HERV-K PROTEINS IN CANCER DEVELOPMENT 
 
Cancer Development Theories 
Cancer develops when cell signaling pathways become impaired. These 
aberrant cells are unresponsive to apoptotic signals and tend to aggressively 
multiply. There are a couple theories to the development of cells with a deviant 
phenotype. The stem cell theory of cancer proposes that cancerous cells arise 
from a subset of cancer cells that have characteristics of normal stem cells (Laks, 
Visnyei, and Kornblum 2010). These cancer stem cells (CSC) undergo 
differentiation and self-renewal and act as a generator of the cancerous cells that 
will result in a tumor, which contrasts with the clonal evolution cancer theory 
where any cell that escape regulation of the cell cycle can become a cancerous 
cell. These differences are visualized in Figure 3. The stem cell theory has 
several implications for cancer therapeutics. Malignant cells that have a 
phenotype characteristic of a CSC often persevere after chemotherapy. Because 
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of their ability to generate new cancer cells, it is hypothesized CSCs are also 
responsible for the propagation and relapse of cancer (Argaw-Denboba et al. 
2017). Regardless of the development theory, several studies have suggested 
that HERV-K is associated with cancer, especially in deviant cells displaying 
aggressive and metastatic tendencies. In other words, targeting cells with 
extensive HERV-K expression covers the therapeutic targets indicated in both 
cancer models. 
 
Figure 3: CSC and Clonal Evolution Models of Cancer Development. The 
CSC model suggests that cancerous cells arise from differentiation of a small 
population of cancer stem cells, and therapeutics should target these CSCs. On 
the other hand, the clonal evolution model implies that any cell has the potential 
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to switch a cancerous phenotype, providing a larger cell population for 
therapeutic agents (Laks, Visnyei, and Kornblum 2010). 
Mechanisms of increased HERV-K expression 
Expression of HERV-K transcripts are considerably elevated in germ cell 
tumors (GCT), ovarian cancers and melanoma, to name a few, while the majority 
of healthy tissues and benign tissues show little if any signs of transcription 
(Hohn, Hanke, and Bannert 2013). Protective mechanisms against HERV-K 
particles are also enacted by the cell, and research has shown that HERV-K 
transcription activity often correlates with level of CpG methylation in cancer cell 
lines (Stengel et al. 2010).  Cells that showed an increase in HERV-K transcripts 
also produced antibodies, which appear to have anti-tumorigenic properties 
(Zhou et al. 2015). Furthermore, a strong association between the presence of 
HERV-K antibodies and the clinical manifestations of GCT have been 
characterized (Hanke, Hohn, and Bannert 2016).  
The debate whether cancer enhances HERV-K expression or whether 
proviruses induce malignant pathogenesis is ongoing, but it is still important to 
identify mechanisms leading to increased HERV-K transcriptional states. Within a 
cell, possible intracellular mechanisms for HERV-K activation include chromatin 
remodeling via hypomethylation and transcription factor binding. 
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Figure 4: Proposed Mechanisms of HERV-K Activation and Tumor 
Proliferation. Major intracellular methods of activation of HERV-K transcription 
include hypomethylation of HERV-K promoters, binding of transcription factors 
and hormone receptors, and expression of Rec and Np9 accessory proteins. 
More specifically, Rec and Np9 bind to regulators of AR and c-Myc, leading to an 
increase in AR and C-Myc activity, known to induce pro-proliferative cell states 
(Hanke, Hohn, and Bannert 2016). 
 
HERV-K LTRs are often hypomethylated in tumorigenic states, leading to 
activation of proviral transcription in various cancers (Stengel et al. 2010). 
Although global hypomethylation is a common epigenetic event seen in 
malignant disease, HERV-K hypomethylation is also correlated with age, and is 
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therefore capable of inducing cancer development as a patient ages (Wallace et 
al. 2014). 
Additionally, numerous transcription factors also contribute to upregulation 
of HERV-K expression. Sp1 and Sp3 are common zinc finger proteins that bind 
to GC boxes of many promoters (Fuchs et al. 2011). They are responsible for 
regulating genes that control cell growth, differentiation, apoptosis, DNA damage, 
and chromatin remodeling. In the context of HERV-K, the 5’LTR regions contains 
several binding sites for transcription factors. Of the binding sites that are 
conserved in the majority of the 5’ LTR region, binding sites for both Sp1 and 
Sp3 are included (Manghera and Douville 2013). Interestingly, the TATA box 
promoter is absent from HERV-K LTRs and an alternative initiator sequence is 
not present. Instead, many of these LTR regions contain 4 G-rich regions, 
providing nucleosome-free binding regions for Sp1 and Sp3. HERV-K transcripts 
undergo a distinct initiation process that is mediated through binding of these 
transcription factors to HERV-K LTRs (Fuchs et al. 2011). Although proviral 
promoter activity depends on the degree of accumulated mutations and 
insertions, Sp1 and Sp3 binding can free some of the many HERV-K 
transcription start sites, which allow for various degrees of TATA-independent 
transcription of HERV-K genes (Hurst and Magiorkinis 2017). The presence of 
alternative transcription start sites also provides more than one location at which 
transcription can be initiated, and represents an additional mechanism for 
heightened HERV-K expression (Persson et al. 2016). 
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Common hormones also play a role in stimulation of HERV-K expression 
through their ability to act as transcription factors. HERV-K expression is often 
associated with malignancies in hormone-regulated tissues and analysis of 
HERV-K promoters indicate the presence of several response elements (RE) that 
react to estrogen, progesterone, androgens, and glucocorticoids (Manghera and 
Douville 2013). Studies have demonstrated that a significant increase in HERV-K 
transcription follows estradiol and progesterone treatment in breast cancer cell 
lines (Golan et al. 2008), and that androgen-regulated cell lines increase proviral 
protein expression in the presence of androgens (Hanke et al. 2013). 
Furthermore, accessory proteins, Rec and Np9, originating from the alternative 
splicing of HERV-K sequence can contribute to increased transcription of proviral 
sequences. The proposed route of increased HERV-K expression and resulting 
tumor proliferation due to these proteins, will be discussed further on in this 
paper. 
In addition to the molecular mechanisms recruited to increase HERV-K 
expression, it is possible that horizontal infection of HERV-K particles can 
stimulate transcriptional events in neighboring cells. While research has yet to 
identify HERVs in the human genome that code for fully infectious virus, 
contributions of functional HERV-K genes from the diverse number of HERV-K 
loci have retained the coding capacity for every protein necessary for viral 
infection (Belshaw et al. 2004). Currently, the predominant view is to doubt the 
infectious potential of HERVs, but recent studies have identified that HERV-K 
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particles are transmissible and their packaged genetic information can undergo 
reverse transcription once fusion with a neighboring cell is complete (Contreras-
Galindo et al. 2015). After fusion, most complementary DNA sequences formed 
1LTR and 2LTR episomes, but chromosomal integration was not identified. 
However, the nature of the experiment may have favored autointegration rather 
than chromosomal integration, and this ambiguity prompts the necessity of 
further studies. Nevertheless, it is likely that these episomes are able to 
transcribe and translate HERV-K material (Contreras-Galindo et al. 2015). This 
could contribute to the elevated levels and potentiate the horizontal infection into 
neighboring cells. Additionally, acquisition of viral envelopes such as vesicular 
stomatitis virus (VSV) would increase the success of the HERV-K infection by 
several fold (Tyagi et al. 2017), as indicated in figure 8a, but mutations necessary 
to develop a similar envelope are unlikely to occur. 
 It has also been theorized that many retroviruses can act synergistically 
and research, although conflicting, has indicated that HIV particles have also 
been associated with heightened levels of HERV-K (van der Kuyl 2012).  
Efficiency of HERV-K horizontal infection is also positively influenced in presence 
of HIV-1 Tat and Vif (Contreras-Galindo et al. 2015), as well as the HERV-K Rec 
accessory protein. Due to HIV’s ability to increase the expression of HERV-K, it 
is not surprising that HIV-infected persons show a higher risk for cancer 
development; the enhanced risk can range from a 2-3 fold risk for cancers such 
as melanoma, lung cancer, and hepatocellular cancer, to a staggering ten to 
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thirty fold risk for anal cancer and non-Hodgkin’s lymphoma (Sigel et al. 2011). 
However, it is uncertain which viral particle instigates propagation so further 
research is required. 
 
Associations and Mechanisms of HERV-K Mediated Oncogenesis  
There are three likely mechanisms through which HERV-k proteins can 
contribute to oncogenesis: immunosuppression, insertional mutagenesis, and 
direct oncogenic activity. Due to its immunosuppressive domain, escape from 
immune system surveillance is a typical role of most retroviral Env proteins, and 
would be a plausible contributor to cancer development. This function is 
demonstrated in a viral particle’s ability to fuse with a cell without an immune 
response during the viral reproductive cycle and in processes such 
placentogenesis. 
 Insertional mutagenesis refers to activation of proto-oncogenes via 
insertion of proviral sequences. HERVs are known to pose an influence over 
neighboring genes by acting as transcription factors through provision of 
alternative promoters (Dunn, Medstrand, and Mager 2003). These promoters, 
which are often solo LTRs generated from recombination events that remove 
internal gag, pro, pol, and Env genes, are often hypomethylated and allow for 
recruitment and binding necessary transcription factors and proteins, ultimately 
leading to increased expression of downstream genes and, potentially, cell 
proliferation. This mechanism of HERV induced pathogenesis is seen in 
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Hodgkin’s Lymphoma, resulting in impaired regulation of the proto-oncogene 
colony-stimulating factor 1 receptor (CSF1R) (Lamprecht, Bonifer, and Mathas 
2010). However, translocation of HERV sequences can also disrupt the stability 
or lead to the inactivation of tumor suppressor genes (Kurth and Bannert 2010). 
Furthermore, HERV-K inserts lead to expression of transcription factors 
that lead to oncogenesis. After transfecting embryonic kidney 293T cells line with 
a vector expressing the HERV-K Env, Tsang et al found that HERV-K was able 
to modify expression of 86 genes (17 upregulated and 69 downregulated). Of the 
upregulated genes, those that showed greatest increase in expression were 
transcription factors that include EGR1, ETV4, ETV5 and FosB. These 
transcription factors have been associated with promotion of epithelial to 
mesenchymal transition (EMT) and tumor aggression in cancers such as prostate 
and endometrial cancer (Currie et al. 2017). While the conclusion drawn from this 
study are indeed interesting, more studies should be done in vitro so the sample 
subject is more representative of the environment, eliminating potential threats to 
the study’s external validity. Nevertheless, this correlation can serve as a segue 
into HERV-K’s direct oncogenic role.  
The third and most direct mechanism of malignant disease progression is 
the possibility that HERVs encode for proteins that are capable of switching a 
healthy cell’s phenotype to that of a cancerous cell. Previously, studies have 
indicated that Env protein from retroviral sequences had the ability to induce 
tumor formation on its own, as well as demonstrated phenotypic switching, 
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leading to tumor formation in vivo (Hofacre and Fan 2004). A recent study 
demonstrated that expression of HERV-K induces epithelial-mesenchymal 
transition (EMT), where a loss of cell polarity induces a loss of function. The 
change in phenotype is seen in the cell’s increased mobile capability and, 
therefore, metastatic potential (Tsang et al. 2017). The study used a non-
transformed breast epithelial MCF10A cell line, showing HERV-K Env increased 
the levels of fibronectin and N-cadherin while decreasing E-cadherin, a result 
characteristic of EMT. 
Furthermore accessory proteins Rec and Np9 are other potential 
oncogenes due to their interaction with cancer-related structures. Rec is one of 
the notable products from alternative splicing of the HERV-K Env transcript and 
facilitates nuclear export of HERV-K mRNA (Contreras-Galindo et al. 2015). 
Additionally, it may contribute to development of a precancerous state; mice with 
increased Rec expression lesions similar to those seen in humans with classical 
seminoma. In cells with co-expression of Rec and promyelocytic leukemia zinc-
finger protein (PLZF) show an increase in cell proliferation and reduced 
apoptosis. PLZF functions as a negative regulator of the c-myc protooncogene, 
but its proficiency is impaired when Rec binds (Denne et al. 2007). In contrast to 
Np9, Rec also has the ability to increase HERV-K replication. In the testes, Rec 
can also form complexes with testicular zinc-finger protein (TZFP) and human 
small glutamine-rich tetratricopeptide (hSGT) and prevent binding to the 
androgen receptor (AR). Because TZFP and hSGT usually depressed AR’s 
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actions, Rec therefore tampers with hSGT and TZFP’s ability to hold AR in the 
inactive state. The presence of androgens has been linked to further expression 
of HERV-K via recruitment of transcription factors to HERV-K LTRs (Manghera 
and Douville 2013). This propagates the expression of HERV-K particles, and 
amplifies other effects of proviral expression seen in Figure 4. 
Np9, another alternatively spliced product of the HERV-K Env transcript, 
has similar abilities to Rec but does not exhibit any influence over the enhanced 
replication of HERV-K sequence. Considering Np9 shares the same starting 
sequence of amino acids as Rec, it is not surprising that it shares Rec’s ability to 
bind to PLZF protein, leading to increased c-myc transcription and malignant cell 
properties (Denne et al. 2007). Additionally, misregulation of the MAPK Pathway 
is also a demonstrated result of Np9 expression. Numb and Notch are both 
regulative protein of the MAPK pathway, the former acting as an antagonist to 
the latter, which is a transcription factor that promotes the Ras signaling cascade. 
Interaction of Np9 with a ligand of Numb ubiquinates the negative regulator of the 
Ras cascade, and leading to proteolytic degradation of Numb (Armbruester et al. 
2004). However, it is important to note that the mechanism through which these 
accessory proteins act is still elusive and that both are expressed in various 
types of human tissue cells, indicating that their expression is not restricted to 
disease states (Schmitt et al. 2015).  
Melanoma 
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HERV-K expression has long been associated with melanoma, which has 
the highest mortality among skin cancers. Studies demonstrated that UV 
radiation, the most established environmental risk associated with melanoma 
occurrence, leads to specific HERV-K activation (Schanab et al. 2011), and 
increased levels of HERV- K particles and associate antibodies and T-
lymphocytes could be detected in melanoma patients (Stengel et al. 2010). 
Despite efforts to characterize HERV-K’s role in melanoma progression, it was 
uncertain if the provirus actively participated in tumorigenesis and concealment 
from immune surveillance or it was activated as a byproduct of malignant 
transformation (Schmitt et al. 2013). 
However, recent studies have implicated that malignant melanoma cells 
with CD133+ stemness features require HERV-K to induce the phenotype switch 
(Argaw-Denboba et al. 2017), adding to the evidence that HERV-K has direct 
oncogenic activity. In melanoma, tumors are comprised of cells that show distinct 
morphological and phenotypic profiles, and are therefore referred to as 
heterogeneous tumors. Different intra- and extra-cellular markers can be used to 
target and characterize cells that show high self-renewal capacity and 
tumorigenic potential within the population of cancerous cells. Of the markers 
used to identify CSCs, studies have suggested that those supporting CD133 
positive (CD133+) features had particularly troublesome capabilities. Due to a 
CD133+ cell’s association with enhancement of tumor initiation and metastasis, 
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inhibition of apoptosis, and resistance to chemotherapy, the CD133 cell marker is 
widely used to characterize and isolate melanoma CSCs in studies.  
When comparing the ability for different melanoma cell lines to undergo 
phenotype switching that lead to the expression of CD133, only those with a 
significant increase in relative expression of HERV-K became CD133+ (Argaw-
Denboba et al. 2017). Furthermore, analysis of relative composition of CD133+ 
cell lines where HERV-K expression was inhibited indicated a significant 
decrease in CD133+. Cell cultures demonstrated a visible reduction in cell growth 
in these HERV-K inhibited lines (Argaw-Denboba et al. 2017).  
A possible mechanism through which HERV-K fosters CD133+ expression 
and emerging CSCs is via activation of the Ras-Raf-Mek (MAPK) Pathway. 
Notably, RAS mutations are the most common type of abnormality in 
protooncogenes in human tumors and protooncogenes were first discovered in 
retroviruses. Several studies have indicated that 80% of all cutaneous melanoma 
arise from irregular activation of this pathway (Wang and Qi 2013), and although 
cutaneous melanoma is not the most common result of the mutation, it is the 
most aggressive. A recent study had indicated that HERV-K Env activates the 
MAPK Pathway, via ERK1/2 phosphorylation and transcription factor expression 
(Tyagi et al. 2017). Phosphorylation leads to activation of kinase activity, which 
plays a major role in regulating cell division. Similar activation of kinases is seen 
in Jaagsiekte Sheep Retrovirus (JSRV), which has a strong oncogenic effect (De 
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las Heras et al. 2006). However, this ability not observed in any other retroviral 
Env, as indicated in Figure 5.	 
Considering JSRV’s oncogenic effect has been described previously, the 
parallels seen in between HERV-K and JSRV suggests that HERV-K 
modification of the MAPK pathway is a plausible means to oncogensis (Tsang et 
al. 2017). Results from studies exploring HERV-K role in pancreatic cancer also 
demonstrated that downregulation of the HERV-K Env protein leads to 
decreased expression of MAPK intermediates (Li et al. 2017), strengthening the 
proposed mechanism through which HERV-K initiates cancer. 
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Figure 5: Oncogenic Properties of Different Retroviral Envs. (A) Shows 
ability for various retroviral Envs to phosphorylate ERK1/2. (B) Expression of 
transcription factors EGR1, ETV4, and ETV5 following transcription of Env 
particles. (C) Transforming activity of Ampho, HERV-K, JSRV, and enJSRV. (D) 
Phosphorylation of ERK ½ in cells expressing Ampho, HERV-K, JSRV, and 
enJSRV. (E) Expression of transcription factors EGR1, ETV4, and ETV5 
following transcription of Env particles. (F) Levels of viral titre of Env particles 
(Tsang et al. 2017). 
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Breast Cancer 
 Of all of the cancers relevant to HERV-K, breast cancer is the most 
common and the leading cause of cancer death in woman worldwide. In breast 
cancer there are four intrinsic subtypes determined by The Cancer Genome Atlas 
Network: basal, Her2E, Lum A, and Lum B (Johanning et al. 2017). Like most 
cancers, the HERV-K is overexpressed in breast cancer in several studies 
despite epigenetic silencing of HERV-K in most healthy tissues, but the subtypes 
that demonstrated this elevation were not identified (Johanning et al. 2017). To 
resolve if one or more subtypes showed increase in HERV-K expression, 
Johanning et al measured the levels of expression of 4 different HERV-K loci in 
each of the breast cancer subtypes. Interestingly, their research demonstrated 
that the greatest levels of HERV-K expression is seen in the basal subtype, 
which is notably the most aggressive of the breast cancers. This postulates the 
aggressive behavior of the basal breast cancers cells may be driven by the 
difference in expression of HERV-K, as serum HERV-K levels are strongly 
indicative of metastatic potential at the time of breast cancer diagnosis (Wang-
Johanning et al. 2014).  
 In their experiment, HERV-K108, HERV-K109, HERV-K113, and HERV-
K115 were selected because these loci were capable of creating infectious viral 
particles capable of integrating additional HERV-K sequences in neighboring 
cells and can be found on different chromosomes throughout the genome. 
Because it is unlikely for HERV-K transcription to be limited to one chromosome, 
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the variation in chromosome location provides a more representative response of 
transcriptional events in the human genome. Interestingly, regardless of the 
locus, the basal subtype consistently expressed higher levels of HERV-K 
transcripts when compared to the other three (Figure 6) (Johanning et al. 2017). 
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Figure 6: Levels of HERV-K Expression in BC Patient Tumors. Expression of 
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HERV-K (a) env, (b) pro, (c) gag, and (d) pol transcripts were from different loci 
(HERV-K108, K109, K113, and K115) in BC tumors was evaluated. (e) 
Percentage of cells expressing higher or lower than average levels of Env 
proteins depending on BC subtype (Johanning et al. 2017). 
This finding, consistent through each combination of subtype and HERV-
transcript, implies that the basal subtype has additional mechanisms that lead to 
upregulation and increased integration of HERV-K sequences (Johanning et al. 
2017). Additionally, although the increase was significant throughout each 
HERV-K gene, the Env transcript had smaller p-values by several orders of 
magnitude, and further studies clarifying the different roles of HERV-K transcripts 
and products should be initiated. 
Contributions of HERV-K Env protein to breast cancer development have 
also been explored. In vivo studies have witnessed a decrease is breast tumor 
size and weight in mouse xenografts of 3 different breast cancer (BC) cell lines 
transduced with a HERV-K inhibiting or control vector (Zhou et al. 2015). 
Significantly greater expression of HERV-K was observed in mice infected with 
the control vector, conserving the plausibility that tumor progression is 
attributable to heightened levels of HERV-K env. Long term cultures of the same 
cells yielded similar results; there was a significant reduction in the size and 
number of colonies in the BC cell lines that were not able to effectively produce 
HERV-K products (Zhou et al. 2016). Using the Ingenuity Pathway Analysis 
program, a comprehensive analysis tools that identifies relevant signaling and 
metabolic pathways associated with certain levels of expressed genes, HERV-K 
	29 
knockdowns show a decrease in epidermal growth factor receptor (EGFR) 
expression. EGFR contains downstream pathways that regulate EMT, resulting 
in enhanced migration and metastatic abilities, and is usually overexpressed in 
BC cells. Reduction in vimentin and CK-19, characteristic mesenchymal and 
epithelial markers, respectively, upon an increase in HERV-K expression 
confirmed that the observed phenotype switch followed enhanced transcription.  
Similar to the research seen with CD133+ melanoma cells, signaling 
changes in the MAPK pathway was observed after knockdown of HERV-K 
(Argaw-Denboba et al. 2017). Due to depression of Ras, p-ERK ½, and p-RSK, 
all of which are players in the MAPK pathway, which have been proposed to play 
an important role in activation of HERV-K expression (Huang et al. 2013), 
knockdown cells showed less proliferative and migratory abilities.  
Many of the studies investigating HERV-K’s correlation and role in 
malignant disease have reached similar conclusions: increased production of 
retroviral particles leads to malignant disease via interruption of the MAPK 
pathway and induction of EMT. The shared result makes HERV-K products a 
promising target for cancer pharmaceuticals and is certainly worth investigating.  
The next part of the paper will explore the possible applications of 
antiretroviral drugs that may depress expression of HERV-K transcripts. 
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ANTIRETROVIRAL DRUGS 
Antiretroviral Therapy (ART) is the use of any of several classes of 
antiretroviral agents that act to inhibit different stages of the viral life cycle. While 
these therapeutics will not directly kill viruses, inhibition of vital process can slow 
down rate of infection. Currently, there are 26 FDA-approved antiretroviral drugs, 
which function via inhibition of proteins crucial to the retroviral replication cycle. 
Depending on which protein it targets, these drugs can be classified as entry 
(fusion) inhibitors, protease inhibitors, integrase (IN) inhibitors, or reverse 
transcriptase (RT) inhibitors, which is further broken down into nucleotide RT 
inhibitors (NRTIs) and non-nucleotide RT inhibitors (NNRTIs). These drugs are 
often used in combination to delay the progression of HIV infection, a practice 
more commonly known as highly active antiretroviral therapy (HAART). 
 
Efficacy of ART in lowering HERV-K Expression 
Entry inhibitors block targets relating to viral binding, fusion and entry into 
a host cell. However, because HERV’s are endogenous elements and their 
infectious potential is not widely supported, this class of therapeutics is unlikely to 
exert a significant effect on the HERV-K lifecycle and research regarding this 
class’s effect on HERV-K expression has not been conducted. 
Of the 3 proteins relevant to the HERV-K lifecycle, RT plays the most 
central role, making it the biggest target for pharmaceutical inhibition. RT 
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Inhibitors can be divided into 2 subgroups. NRTIs are structural analogues of the 
bases that make up genetic information. However, they lack a 3’OH, which is 
necessary to continue elongation of a DNA strand. Incorporation by RT into a 
growing DNA strand results in premature termination (Tyagi et al. 2017). 
On the other hand, NNRTIs, as indicated in their name, are not analogous 
in structure to nucleotides, and will, therefore, not act to terminate a growing DNA 
sequence. Instead, NNRTIs bind to the NNTRI binding pocket, found near the 
polymerase active site of the RT, effectively preventing the alignment of the 3’ 
end with the polymerase responsible for extension. In other words, the 
conformational shift caused by NNTRI interaction diminished the efficiency and 
ability of the RT itself (Argaw-Denboba et al. 2017). 
When attempting to characterize the effect of FDA-approved antiretroviral 
drugs on HERV-K expression and products, Tyagi et al. found that nucleotide RT 
inhibitors (NRTI) and non-nucleotide RT inhibitors (NNRTI) lead to a significant 
dose-dependent inhibition of HERV-K RT activity (Figure 7; Tyagi et al. 2017)). 
The efficacy of these FDA-approved HIV medications also was reflected in 
similar IC90 values, indicating that the necessary dose to show the desired effect 
would be safe in the human population. Concomitantly, a decrease in overall 
HERV-K expression was observed, as measured by relative expression of 
HERV-K gag (Figure 8). 
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Figure 7: Reverse Transcriptase Inhibitors reduce activity of HERV-K RT.  
The percent inhibition of HERV-K RT compared to no treatment of (a) Nucleoside 
RT Inhibitors and (b) Non-nucleotide RT Inhibitors was measured. The control 
did not receive any treatment and is assumed to have 0% inhibition at all 
concentrations (Tyagi et al. 2017). 
 
Figure 8: HERV-K Expression is Effectively Inhibited by Different Classes of 
Antiretroviral Drugs. (a) VSV-G pseudotyped particles facilitated more 
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successful HERV-K infection and increased expression by several fold. (b-d)  
HERV-K infected cells showed inhibition of proviral expression upon 
administration of (b) Abacavir, a NRTI, (c) AZT, a NNRTI, and (d) Raltegravir, an 
IN inhibitor (Tyagi et al. 2017) 
 
The ability of RT inhibition by HIV-1 RT inhibitors is likely attributed to the 
fact that RT derived from a consensus HERK-K sequence has a 25% sequence 
homology with HIV-1 RT, as demonstrated through a sequence alignment. 
Comparative modeling using HIV-1 RT complexing with Efavirenz, Nevirapine, 
and Etravirine as a template suggests that NNRTIs bind to HERV-K RT in a 
hydrophobic cavity at an allosteric site (Tyagi et al. 2017). The model, shown in 
Figure 9, shows an inconsistent composition of amino acids in the NNRTI-binding 
pocket, but despite the fact that not all the components of the binding are 
conserved, small NNTRIs (Efavirenz and Nevirapine) were still able to bind. 
Extravirine, which is much larger molecular compound, showed signs of steric 
hindrance. Although small adjustments to amino acid composition eventually 
allowed docking of Extravirine, it would seem that future therapeutic attempts at 
creating NNTRIs for HERV-K RT inhibition should avoid bulkier molecules. 
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Figure 9 Comparative modeling of HERV-K RT and HIV RT. (a) Sequencing 
alignment of HERV-K and HIV RT. (b) Final Model of HERV-K RT showing P51 
and P66 subunits. The red oval indicates the NNRTI-binding region. (c–e) 
Efavirenz, Nevirapine, and Etravirine, respectively bound to the NNRTI-binding 
pocket. Non conserved residues are colored red, green the conserved between 
HERV-K and HIV-1 RT. The NNRTIs are colored with their carbon atom in 
magenta. The magenta underlined sequence are residues lining the NNRTI-
binding pocket (Tyagi et al.). 
When viral sequences are translated from mRNA, the resulting 
polypeptide sequence contains several individual proteins that are unable to 
function until they are separated from their genetic neighbors. This is the function 
of viral proteases: to cut the protein chain into individual enzymes, allowing gene 
products to act and exhibit their intended effect. HERV-K protease is encoded in 
the pol gene of the HERV-K sequence. Although it only shares a 28% amino acid 
consensus with HIV-protease, HERV-K protease contains many of the same 
active domains and a signature motif of Asp-Thr-Asp when compared to HIV 
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protease (Tyagi et al. 2017). These shared domains provide a plausible 
mechanism through which HIV protease inhibitors could depress HERV-K 
protease function. Tyagi et al demonstrated the all protease inhibitors where 
capable of significantly inhibiting the production of functional HERV-K proteins in 
a dose dependent manner, shown by the absence of mature HERV-K proteins in 
cell lysates and viral particles (Tyagi et al. 2017). Ultimately, HERV-K replication 
was unable to proceed in the presence of protease inhibitors. While HIV-protease 
inhibitors were able to significantly inhibit the functional abilities of HERV-K 
protease, the IC90 of the most effective inhibitors still was 20-50 times higher 
than that need for HIV protease inhibition. This staggering IC90 poses a health 
concern for patients: the concentration of inhibitor needed to be effective may 
approach a lethal concentration. The results indicate that the currently available 
array of protease inhibitors is not appropriate for HERV-K protease inhibition, but 
antiretroviral therapy for HERV-K could still be effective if a more specific and 
potent inhibitor for HERV-K was developed. 
The effects of integrase (IN) inhibitors on HERV-K function have also been 
explored. IN is another enzyme vital to the retroviral life cycle. Like protease, it is 
coded in the pol gene, but functions to integrate cDNA into the host genome 
(Hare et al. 2010). Comparative modeling demonstrated that the active sites of 
HERV-K IN and prototype foamy virus (PFV) IN are nearly identical; the only 
noted difference was substitution of a proline with a serine residue (Tyagi et al. 
2017). Because PFV IN can be effectively inhibited by Raltegravir, one of the 3 
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IN inhibitors that are FDA approved, it is not surprising that the drug was also 
capable of inhibiting HERV-K replication (Hare et al. 2010).  
Efficacy of lowering oncogenic properties in cancer cell lines 
While more studies are needed to analyze the effect of antiretroviral drugs 
on cancerous cells, the few studies that have been published have gathered 
evidence supporting the effectiveness of these drugs against malignant disease 
progression. Previously, two NNTRI’s used to treat HIV, Nevirapine and 
Efavirenz, were shown to be effective at reducing proliferation and inducing 
differentiation of TVM-A12 melanoma cell lines (Sciamanna et al. 2005), but 
follow up studies have also identified that these NNTRIs were also effective in 
inducing apoptosis of CD133+ melanoma cells (Argaw-Denboba et al. 2017). In 
an ex vivo medium, where increased HERV-K expression is usually observed 
along with an increased percentage of CD133+ expressing cells, cell lines 
subject to Nevirapine and Efavirenz were unable to activate HERV-K expression 
and showed a parallel decrease in CD133+ expression (Argaw-Denboba et al. 
2017, 13). The data show in Figure 10 provides evidence that the endogenous 
transition to cells with enhanced self-renewal, metastatic, and aggressive 
characteristics can potentially be halted using existing anti-retroviral drugs. 
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Figure 10: NNRTIs are effective to restrain HERV-K activation and induce 
apoptosis in TVM-A12 CD133+ cells. Effects of NNRTIs on the expansion and 
	38 
maintenance of CD133+ cells in TVM-A12 (a) and TVM-A12-CD133+ (b) cell 
lines analyzed by flow cytometry analysis. Effects of NNRTIs on apoptosis levels 
in TVM-A12 (c) and TVM-A12-CD133+ (d) analyzed by flow cytometry analysis 
after nuclei staining with propidium iodide. Relative mRNA expression of HERV-K 
Env gene (e) and CD133 (f) analyzed by Real-time PCR. Data represent the 
results of three independent experiments (Argaw-Denboba et al. 2017, 13). 
 
CONCLUSION AND FUTURE RESEARCH DIRECTIONS 
Although previously written off as “junk DNA,” some HERVs maintain the 
ability to produce functional products despite major inactivation by post-insertion 
mutations and silencing by epigenetic factors. Increased HERV-K expression is 
associated with age, but can also be mediated through several cell signaling 
pathways and affected by the presence of other viral particles. Consequently, 
increased levels of HERV-K proviral activity is hypothesized by several studies to 
lead to the development of cancer. The notion to use antiretroviral drugs to 
combat cancer progression is a fairly novel idea, and as a consequence much 
more research needs to be conducted before drug development becomes 
reasonable. As of now, research has identified that HERV-K proteins are highly 
sensitive to NRTIs, NNRTIs, and IN inhibitors, and these therapeutics can be 
administered to effectively decrease the activity of HERV-K products. While 
protease inhibitors were also effective, the doses required to observe the desired 
effect were too large to be safe and additional research would be necessary to 
develop a protease inhibitor more specific to HERV-K protease. In relation to 
antiretroviral drugs on malignant disease progression, NNRTIs were shown to be 
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extremely effective in inducing apoptosis in melanoma cells with CSC features by 
reducing their proviral expression. In addition to being much more affordable than 
classic chemotherapy treatments, antiretroviral drugs also provide alternative 
treatments for other pathologies associated with HERV-K expression outside the 
scope of cancer. The results and additional benefits suggest that HERV-K can 
serve as a promising new target in pathologies not limited to cancer. Developing 
more HERV-K specific therapies can increase potency and efficacy of 
antiretroviral compounds, but future research should continue focus on the exact 
mechanism of HERV-K mediated pathogenesis to clarify and confirm the 
proposed association.  
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